There is significant variation in the uptake of cancer risk reducing options by women with a BRCA1 or BRCA2
mutation. It is currently unclear why these differences exist and it is
possible that recommendations vary between providers and these
influence patient decisions.
healthcare providers who provide genetic counseling for hereditary
breast and ovarian cancer families in Canada were identified. Each
provider was asked to complete a study specific questionnaire that
included their opinion of various cancer risk reduction options and
their recommendations for specific cases.
Respondents recommended prophylactic oophorectomy more often than prophylactic mastectomy or tamoxifen for women with a BRCA1 or BRCA2
mutation (p < 0.0001). Fewer than half of the respondents agreed
with the recommendation for prophylactic mastectomy, and a minority of
the respondents supported the recommendation for tamoxifen for
majority of Canadian genetics health care providers adhere to the NCCN
Guideline of recommending prophylactic oophorectomy to mutation
carriers, however, the minority of genetics health care providers
recommend either prophylactic mastectomy or tamoxifen.